{
  "nodes": [
    {
      "id": "node_001",
      "content": "PD-L1 ≥1%",
      "parent_ids": [],
      "children_ids": [
        "node_002"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "nn",
        "ttt"
      ]
    },
    {
      "id": "node_002",
      "content": "Biomarker-directed therapy (NSCL-J 2 of 6)",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_003",
        "node_005"
      ],
      "tree_ids": [
        "NSCL-J 2 of 6"
      ],
      "footnote_labels": [
        "rr",
        "uuu"
      ]
    },
    {
      "id": "node_003",
      "content": "Response or stable disease",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_004"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_004",
      "content": "Continuation maintenance",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_006"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "rr"
      ]
    },
    {
      "id": "node_005",
      "content": "Progression",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_006"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_006",
      "content": "Systemic Therapy (NSCL-K 1 of 5) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)",
      "parent_ids": [
        "node_004",
        "node_005"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 1 of 5",
        "NSCL-K 4 of 5"
      ],
      "footnote_labels": [
        "vvv"
      ]
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-38",
      "to_tree": "NSCL-J",
      "description": "Biomarker-directed therapy guidelines"
    },
    {
      "from_tree": "NSCL-38",
      "to_tree": "NSCL-K",
      "description": "Systemic Therapy guidelines"
    },
    {
      "from_tree": "NSCL-38",
      "to_tree": "NSCL-H",
      "description": "Principles of Molecular and Biomarker Analysis"
    }
  ],
  "footnotes": [
    {
      "label": "nn",
      "content": "Principles of Molecular and Biomarker Analysis (NSCL-H)."
    },
    {
      "label": "rr",
      "content": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J)."
    },
    {
      "label": "ttt",
      "content": "Contraindications for treatment with PD-1/PD-L1 inhibitors may include active or previously documented autoimmune disease and/or current use of immunosuppressive agents; some oncogenic drivers (ie, EGFR exon 19 deletion or L858R; ALK, RET, or ROS1 rearrangements) have been shown to be associated with less benefit from PD-1/PD-L1 inhibitors. If there are contraindications, refer to NSCL-K 1 of 5 (adenocarcinoma) or NSCL-K 2 of 5 (squamous cell carcinoma)."
    },
    {
      "label": "uuu",
      "content": "For patients who require an urgent start to therapy but molecular testing is pending, consider holding immunotherapy for one cycle, unless confirmed that no driver mutations are present."
    },
    {
      "label": "vvv",
      "content": "If patient has not received platinum-doublet chemotherapy, refer to \"systemic therapy.\" If patient received platinum chemotherapy and anti-PD-1/PD-L1, refer to \"subsequent therapy.\""
    }
  ],
  "extraction_confidence": 0.95,
  "image_title": "PD-L1 POSITIVE (≥1%)",
  "tree_id": "NSCL-38",
  "keywords": []
}
